

AF

1385.45510X00

\$ 1631
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert L. CAMPBELL, et al.

Serial No.: 09/359,260

Filed: July 22, 1999

Title: METHOD OF IDENTIFYING PEPTIDES HAVING DESIRED ACTIVITY
LEVELS (as amended)

Group: 1631

Examiner: Eric S. DeJong

Confirmation No.: 2590

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

05/01/2006 JADD01 00000034 09359260
01 FC:1806 180.00 OP

April 28, 2006

Sir:

In the matter of the above-identified application, this Information Disclosure Statement is being submitted with the following citation as specified in 37 CFR §1.97(d).

"A copy of any patent, publication or other information listed in an Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the Office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. §120."

MPEP states that prior art of related cases be made of record. Review of the present and parent files has revealed art from a related case not yet made of record in the present application, and accordingly, provided herewith a copy of Form PTO/SB/08B which list documents cited in related application Serial Nos. 10/087,905

and 10/087,942, both filed on March 5, 2002, respectively, the entire disclosure of which is hereby incorporated by reference, listing such art for Examiner initialing.

Any independent review by the Examiner of the related application(s) and utilization of any necessary Form PTO-892s to ensure that all known prior application art is considered and listed on any patent from the present application, would be greatly appreciated by the Applicant and the undersigned.


It is respectfully requested that this Information Disclosure Statement be considered by the Examiner.

This Information Disclosure Statement is being submitted subsequent to a first Office Action on the merits in the above-identified application, but prior to a Final Office Action or issuance of a Notice of Allowance, or issuance of any other action closing prosecution on the merits in the above-identified application. Accordingly, the fee of \$180.00 is enclosed herewith.

To the extent necessary, please charge any shortage in the fees due or credit any overpayment of fees in connection with the filing of this paper to the deposit account of Antonelli, Terry, Stout & Kraus, LLP Deposit Account No. 01-2135 (Docket No. 1385.45510X00).


Respectfully submitted,

ANTONELLI, TERRY, STOUT & KRAUS, LLP


Leonid D. Thenor
Registration No. 39,397

LDT/vvr

Dated: April 28, 2006



PTO/SB/08B (04-03)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	09/359,260
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	7/22/1999
		First Named Inventor	Robert L. CAMPBELL
		Group Art Unit	1631
		Examiner Name	John S. Brusca
		Attorney Docket Number	1385.45510X00
(use as many sheets as necessary)			
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Zheng et al. Focus-2D: A new approach to the design of targeted combinatorial chemical libraries. Pacific Symposium on Biocomputing Vol. 3, pages 305-316 (1998)	
		Ostrem et al., Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry, Biochemistry, 37:1053-1059 (1998).	
		Tenson et al., Erythromycin Resistance Peptides Selected from Random Peptide Libraries, J. Biol. Chem., 272:17425-17430 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2